Related Experiment Video
Updated: Aug 3, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
2016 ESC and ACC/AHA/HFSA heart failure guideline update - what is new and why is it important?
Mariell Jessup1, Thomas H Marwick2, Piotr Ponikowski3
1Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Building 421, Philadelphia, Pennsylvania 19104, USA.
Insights
New guidelines for heart failure (HF) management have been released by ESC and ACC/AHA/HFSA. This viewpoint discusses updates, differences between guidelines, and future improvements for HF treatment.
Area of Science:
- Cardiology
- Clinical Practice Guidelines
Background:
- Heart failure (HF) is a widespread global health issue with significant morbidity and mortality.
- Despite advancements, HF management continues to evolve with new diagnostic and therapeutic options.
Purpose of the Study:
- To provide expert insight into the recently updated European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) guidelines for HF management.
- To highlight novel aspects, compare differences between the ESC and ACC/AHA/HFSA guidelines, and suggest future improvements.
Main Methods:
- Expert commentary and analysis from the chairs of the ESC Task Force and ACC/AHA/HFSA Writing Committee.
- Inclusion of an independent opinion leader to provide a balanced perspective.
Main Results:
- The updated guidelines incorporate new pharmacological therapies for HF treatment.
- Key differences and similarities between the ESC and ACC/AHA/HFSA guidelines are identified.
Conclusions:
- The updated guidelines represent significant progress in HF management.
- Recommendations for future guideline updates are proposed to further enhance patient care.
Abstract:
Heart failure (HF) is a global epidemic affecting millions of individuals worldwide. Although important progress has been made in the management of HF, this condition remains a common cause of morbidity and death. Since the publication of the previous sets of guidelines for the management of HF, new diagnostic and therapeutic options for HF have emerged. Now, both the ESC and the ACC/AHA/HFSA have simultaneously published an update of their guidelines incorporating, among others, recommendations for the use of new pharmacological therapies for the treatment of HF. For this Viewpoint article, we have asked the chairs of the ESC Task Force, the chairs of the ACC/AHA/HFSA Writing Committee, and an independent opinion leader in the field to offer their expert insight into the new guidelines, highlighting what is new, what the main differences are between the two sets of guidelines, and what steps should be taken to improve the guidelines in future updates.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions

